🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Has anyone dealt with surmount-2: tirzepatide for t2dm + obesity? Page 5

Has anyone dealt with surmount-2: tirzepatide for t2dm + obesity?

claudia_zurich Fri, Jan 31, 2025 at 8:00 PM 37 replies 1,853 viewsPage 5 of 8
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Feb 8, 2025 at 1:44 AM#21
BiostatsBrad said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

42 15DerekSJ_a1c, paige_pharma, emma_london and 39 others
Reply Quote Save Share Report
hyun_seoul
Member
345
1,456
Jul 2024
Seoul, KR
Feb 8, 2025 at 8:30 AM#22

Adding the clinical framing, because it changes how the question reads. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

I would rather be corrected than agreed with, if it comes to it.

Last edited: Feb 8, 2025 at 12:30 PM
43 16GenomicsKate, Dr.ObesityMed, HealthEcon_DC and 40 others
Reply Quote Save Share Report
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Feb 8, 2025 at 3:16 PM#23
hyun_seoul said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Same pattern here, and in the same order.

Last edited: Feb 8, 2025 at 4:16 PM
44 17james_edin, FranDenver, Dr.BariatricHTX and 41 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
JenPlateau
Member
234
890
Nov 2024
Missouri
Feb 8, 2025 at 10:02 PM#24
hyun_seoul said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Adding the part of the answer the thread has not reached. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

Worth separating that from glycaemic control, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

That is the short version; the long version is somebody else's post.

Last edited: Feb 9, 2025 at 4:02 AM
45 18FitDadDave, RunnerRach, TrialNerd_Beth and 42 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Feb 9, 2025 at 4:48 AM#25

One concrete data point for the thread. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

46 19LabKate, kate.chem, DataDave and 43 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register